TY - JOUR
T1 - Improving cervical cancer survival–A multifaceted strategy to sustain progress for this global problem
AU - Markovina, Stephanie
AU - Rendle, Katharine A.
AU - Cohen, Alexander C.
AU - Kuroki, Lindsay M.
AU - Grover, Surbhi
AU - Schwarz, Julie K.
N1 - Funding Information:
Stephanie Markovina reports grant K08CA237822 from the National Institutes of Health outside the submitted work. Katharine A. Rendle reports Administrative Supplements Grants from the National Cancer Institute (3K08CA230170‐03S1 and 3P30CA016520‐45S7); grants from AstraZeneca and Pfizer Canada Inc.; and personal fees from Merck & Company outside the submitted work. Lindsay M. Kuroki reports grants from the National Cancer Institute (Pilot Grant P50 CA24431), the American Association of Obstetrics and Gynecologists Foundation, and the Doris Duke Fund to Retain Clinical Scientists (2015215); service as a fiduciary officer at the American Society for Colposcopy and Cervical Pathology (ASCCP); and travel support from the ASCCP and the GOG Foundation outside the submitted work. Surbhi Grover reports Administrative Supplements Grants from the National Cancer Institute (3K08CA230170‐03S1 and 3P30CA016520‐45S7), a grant from the National Institutes of Health (K08CA230170), and personal fees from Genesiscare outside the submitted work. Julie K. Schwarz reports an American Association for Cancer Research–Bristol‐Myers Squibb Investigator Award outside the submitted work. Alexander C. Cohen made no disclosures.
Publisher Copyright:
© 2022 American Cancer Society.
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Cervical cancer is associated with profound socioeconomic and racial disparities in incidence, mortality, morbidity, and years of life lost. The last standard-of-care treatment innovation for locally advanced cervical cancer occurred in 1999, when cisplatin chemotherapy was added to pelvic radiation therapy (chemoradiation therapy). Chemoradiation therapy is associated with a 30%–50% failure rate, and there is currently no cure for recurrent or metastatic disease. The enormity of the worldwide clinical problem of cervical cancer morbidity and mortality as well as the egregiously unchanged mortality rate over the last several decades are recognized by the National Institutes of Health as urgent priorities. This is reflected within the Office of Research on Women's Health effort to advance National Institutes of Health research on the health of women, as highlighted in a recent symposium. In the current review, the authors address the state of the science and opportunities to improve cervical cancer survival with an emphasis on improving access, using technology in innovative and widely implementable ways, and improving current understanding of cervical cancer biology. Lay summary: Cervical cancer is associated with profound socioeconomic and racial disparities in incidence, mortality, morbidity, and years of life lost. In this review, the state of the science and opportunities to improve cervical cancer survival are presented with an emphasis on improving access, using technology in innovative and widely implementable ways, and improving current understanding of cervical cancer biology.
AB - Cervical cancer is associated with profound socioeconomic and racial disparities in incidence, mortality, morbidity, and years of life lost. The last standard-of-care treatment innovation for locally advanced cervical cancer occurred in 1999, when cisplatin chemotherapy was added to pelvic radiation therapy (chemoradiation therapy). Chemoradiation therapy is associated with a 30%–50% failure rate, and there is currently no cure for recurrent or metastatic disease. The enormity of the worldwide clinical problem of cervical cancer morbidity and mortality as well as the egregiously unchanged mortality rate over the last several decades are recognized by the National Institutes of Health as urgent priorities. This is reflected within the Office of Research on Women's Health effort to advance National Institutes of Health research on the health of women, as highlighted in a recent symposium. In the current review, the authors address the state of the science and opportunities to improve cervical cancer survival with an emphasis on improving access, using technology in innovative and widely implementable ways, and improving current understanding of cervical cancer biology. Lay summary: Cervical cancer is associated with profound socioeconomic and racial disparities in incidence, mortality, morbidity, and years of life lost. In this review, the state of the science and opportunities to improve cervical cancer survival are presented with an emphasis on improving access, using technology in innovative and widely implementable ways, and improving current understanding of cervical cancer biology.
KW - cancer
KW - cervical
KW - chemoradiation
KW - human papillomavirus (HPV)
KW - immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85139749611&partnerID=8YFLogxK
U2 - 10.1002/cncr.34485
DO - 10.1002/cncr.34485
M3 - Review article
C2 - 36239006
AN - SCOPUS:85139749611
SN - 0008-543X
VL - 128
SP - 4074
EP - 4084
JO - Cancer
JF - Cancer
IS - 23
ER -